PMID- 19789403
OWN - NLM
STAT- MEDLINE
DCOM- 20100111
LR  - 20240417
IS  - 1879-0844 (Electronic)
IS  - 1388-9842 (Print)
IS  - 1388-9842 (Linking)
VI  - 11
IP  - 10
DP  - 2009 Oct
TI  - Hawthorn Extract Randomized Blinded Chronic Heart Failure (HERB CHF) trial.
PG  - 990-9
LID - 10.1093/eurjhf/hfp116 [doi]
AB  - AIMS: Hawthorn's efficacy when added to contemporary evidence-based heart failure 
      therapy is unknown. We aimed to determine whether hawthorn increases submaximal 
      exercise capacity when added to standard medical therapy. METHODS AND RESULTS: We 
      performed a randomized, double-blind, placebo-controlled trial in 120 ambulatory 
      patients aged > or = 18 years with New York Heart Association (NYHA) class II-III 
      chronic heart failure. All patients received conventional medical therapy, as 
      tolerated, and were randomized to either hawthorn 450 mg twice daily or placebo 
      for 6 months. The primary outcome was change in 6 min walk distance at 6 months. 
      Secondary outcomes included quality of life (QOL) measures, peak oxygen 
      consumption, and anaerobic threshold during maximal treadmill exercise testing, 
      NYHA classification, left ventricular ejection fraction (LVEF), neurohormones, 
      and measures of oxidative stress and inflammation. There were no significant 
      differences between groups in the change in 6 min walk distance (P = 0.61), or on 
      measures of QOL, functional capacity, neurohormones, oxidative stress, or 
      inflammation. A modest difference in LVEF favoured hawthorn (P = 0.04). There 
      were significantly more adverse events reported in the hawthorn group (P = 0.02), 
      although most were non-cardiac. CONCLUSION: Hawthorn provides no symptomatic or 
      functional benefit when given with standard medical therapy to patients with 
      heart failure. This trial is registered in ClinicalTrials.gov ID: NCT00343902.
FAU - Zick, Suzanna M
AU  - Zick SM
AD  - Department of Family Medicine, University of Michigan, Ann Arbor, MI 48109-0708, 
      USA. szick@umich.edu
FAU - Vautaw, Bonnie Motyka
AU  - Vautaw BM
FAU - Gillespie, Brenda
AU  - Gillespie B
FAU - Aaronson, Keith D
AU  - Aaronson KD
LA  - eng
SI  - ClinicalTrials.gov/NCT00343902
GR  - M01-RR00042/RR/NCRR NIH HHS/United States
GR  - P50 HL 061202 01/HL/NHLBI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PL  - England
TA  - Eur J Heart Fail
JT  - European journal of heart failure
JID - 100887595
RN  - 0 (Plant Preparations)
SB  - IM
MH  - Aged
MH  - Anaerobic Threshold/drug effects
MH  - Chronic Disease
MH  - *Crataegus
MH  - Double-Blind Method
MH  - Exercise Tolerance/*drug effects
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Failure/diagnosis/*drug therapy/mortality
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Oxygen Consumption/drug effects/physiology
MH  - Phytotherapy/*methods
MH  - Plant Preparations/*therapeutic use
MH  - Probability
MH  - Quality of Life
MH  - Reference Values
MH  - Risk Assessment
MH  - Severity of Illness Index
MH  - Stroke Volume/drug effects
MH  - Survival Rate
MH  - Treatment Outcome
PMC - PMC2754502
EDAT- 2009/10/01 06:00
MHDA- 2010/01/12 06:00
PMCR- 2010/10/01
CRDT- 2009/10/01 06:00
PHST- 2009/10/01 06:00 [entrez]
PHST- 2009/10/01 06:00 [pubmed]
PHST- 2010/01/12 06:00 [medline]
PHST- 2010/10/01 00:00 [pmc-release]
AID - hfp116 [pii]
AID - 10.1093/eurjhf/hfp116 [doi]
PST - ppublish
SO  - Eur J Heart Fail. 2009 Oct;11(10):990-9. doi: 10.1093/eurjhf/hfp116.